Latest Breaking News On - Biosight ltd - Page 1 : comparemela.com

NeuroSense Therapeutics : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 27, 2024 - Form 6-K

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 27, 2024 Dear NeuroSense Therapeutics Ltd..

Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors

REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Nov. 06, 2023 (GLOBE NEWSWIRE) Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncol.

Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update

10.08.2023 - Successful End-of-Phase 2 meeting with FDA regarding AL102 for the treatment of desmoid tumors Enrollment in the Phase 3 segment of RINGSIDE trial evaluating AL102 continuing globally as planned Definitive merger agreement with Biosight, expected .

Ayala Pharmaceuticals Merges with Biosight

The combined company will operate under the name Ayala Pharmaceuticals Inc.